PepGen (PEPG) Research & Development (2021 - 2026)
PepGen (PEPG) recorded Research & Development of $12.52 million in Q2 2026, down 31.9% from $18.39 million a year earlier and down 3.7% from the prior quarter.
PepGen (PEPG) Research & Development (2021 - 2026) Analysis & Trends
On a TTM basis, PepGen's Research & Development came in at $52.8 million as of Jun 30, 2026, down 34.4% year-over-year; for FY2025, it came in at $71.04 million, down 7.1% from FY2024.
- Annual Research & Development has a four-year compound annual growth rate of 39.1% (FY2021 to FY2025).
- Across earlier years, Research & Development came in at $76.48 million in FY2024 (+12.3%), $68.13 million in FY2023 (+26.0%), $54.08 million in FY2022 (+184.6%) and $19 million in FY2021.
- The Q2 2026 figure is the lowest quarterly Research & Development since Q1 2022.
- On a year-over-year basis, Research & Development has declined for five consecutive quarters, with an average decline of 10.5% over the last eight quarters.
- Peak year-over-year performance for Research & Development in the last five years was growth of 342.8% in Q2 2022, against a decline of 48.8% in Q1 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at $13 million (Q1 2026), $13.85 million (Q4 2025) and $13.42 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.02 Bn |
| 10 | PepGen | 319.29 Mn | -183.51 Mn | - | 14.48 Mn |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 14.48 Mn |
| Jun 30, 2026 | 12.52 Mn |
| Mar 31, 2026 | 13.00 Mn |
| Dec 31, 2025 | 13.85 Mn |
| Sep 30, 2025 | 13.42 Mn |
| Jun 30, 2025 | 18.39 Mn |
| Mar 31, 2025 | 25.38 Mn |
| Dec 31, 2024 | 18.96 Mn |
| Sep 30, 2024 | 17.72 Mn |
| Jun 30, 2024 | 25.06 Mn |
| Mar 31, 2024 | 14.73 Mn |
| Dec 31, 2023 | 16.30 Mn |
| Sep 30, 2023 | 20.54 Mn |
| Jun 30, 2023 | 16.93 Mn |
| Mar 31, 2023 | 14.36 Mn |
| Dec 31, 2022 | 13.17 Mn |
| Sep 30, 2022 | 15.96 Mn |
| Jun 30, 2022 | 14.24 Mn |
| Mar 31, 2022 | 10.71 Mn |
| Dec 31, 2021 | 4.54 Mn |
PepGen Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=PEPG&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "PEPG", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=PEPG&period=max&api_key=YOUR_API_KEY");
const data = await res.json();